Morfeo (Zaleplon)

Zaleplon enhances the activity of the neurotransmitter GABA by binding to the benzodiazepine site on the GABA_A receptor complex. This positive allosteric modulation increases chloride ion flow into neurons, producing a calming effect that facilitates the onset of sleep without markedly altering the overall sleep structure.

The specific dose of Zaleplon is determined by the prescribing clinician based on the patient’s age, health status, and response to therapy. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

The safety of Zaleplon during pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and clinicians generally avoid prescribing it to pregnant or nursing women unless the potential benefit outweighs potential risks.

To order Morfeo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Zaleplon belongs to the Z‑drug class and is often compared with other non‑benzodiazepine hypnotics such as zolpidem and zaleplon’s older counterpart, benzodiazepines like temazepam. Z‑drugs typically have a shorter half‑life, leading to less next‑day residual sedation, whereas benzodiazepines may cause more prolonged sedation and higher dependence potential.

Morfeo tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and keep out of reach of children. Do not use if the packaging is damaged or the tablets appear discoloured.

Morfeo is taken orally, usually with a full glass of water, shortly before the intended bedtime. It should be taken only when the patient can obtain a full night’s sleep (7–8 hours) and should not be combined with alcohol or other sedating substances.

Serious risks associated with Zaleplon include severe allergic reactions, complex sleep behaviours such as sleep‑walking or sleep‑driving, depression or suicidal thoughts, and respiratory depression when combined with other central nervous system depressants. Patients should seek immediate medical attention if any of these occur.

Morfeo is contraindicated in patients with known hypersensitivity to Zaleplon or any component of the formulation, those with severe hepatic impairment, and individuals who are currently using other CNS depressants such as benzodiazepines, opioids, or alcohol. It should also be avoided in patients with a history of complex sleep‑related behaviours.